BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Naptumomab estafenatox readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Naptumomab estafenatox\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03983954-7668@assetmemo.bio
DTSTAMP:20261121T005938Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Naptumomab estafenatox: Phase 1 readout est. (NCT03983954)
DESCRIPTION:Naptumomab estafenatox\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Naptumomab Estafenatox in Combination With Durvalumab in Subjects 
 With Selected Advanced or Metastatic Solid Tumor\, Including a Cohort Expa
 nsion in Esophageal Cancer.\nEstimated primary completion: 1 March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/naptumomab-estafenatox
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 83954
URL:https://assetmemo.bio/drug/naptumomab-estafenatox#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
